Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q3 2017 · 10-Q
Revenue—
Net Income-$204.41K-$204.41KN/M vs Q3 2016 EPS Diluted-$0.02-$0.02N/M vs Q3 2016 Operating Income-$712,851— Operating Cash Flowderived-$173,687N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Sep 30, 2017 · filed Nov 20, 2017 · 51 d after period end